Hikma assigned investment grade status from Fitch Ratings

London, October 22, 2020 – Fitch Ratings has today announced that it has assigned Hikma Pharmaceuticals Plc (Hikma, Company) a ‘BBB-’ first-time Long-Term Issuer Default Rating (outlook: Stable). Hikma’s existing rating of BBB- (outlook: Stable) from S&P remains unchanged, and accordingly the Company has achieved investment grade status from two rating agencies.

Press Release Corporate 22 October 2020

text 1

Khalid Nabilsi, CFO of Hikma said: “I am pleased to announce that Hikma has achieved investment grade status with two ratings agencies.  Fitch’s announcement today confirms Hikma’s solid market position as well as our track record of profitability and cash generation.”

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.